Repaglinida [Inn-Spanish] en es it fr

Repaglinida [Inn-Spanish] Brand names, Repaglinida [Inn-Spanish] Analogs

Repaglinida [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Repaglinida [Inn-Spanish] Chemical_Formula


Repaglinida [Inn-Spanish] RX_link

Repaglinida [Inn-Spanish] fda sheet

Repaglinida_[Inn-Spanish] FDA

Repaglinida [Inn-Spanish] msds (material safety sheet)

Repaglinida_[Inn-Spanish] MSDS

Repaglinida [Inn-Spanish] Synthesis Reference

W. Grell et al., PCT Int. pat. Appl. WO 93 00,337

Repaglinida [Inn-Spanish] Molecular Weight

452.586 g/mol

Repaglinida [Inn-Spanish] Melting Point

130-131 oC

Repaglinida [Inn-Spanish] H2O Solubility

No information avaliable

Repaglinida [Inn-Spanish] State


Repaglinida [Inn-Spanish] LogP


Repaglinida [Inn-Spanish] Dosage Forms


Repaglinida [Inn-Spanish] Indication

For the treatment of Type II diabetes mellitus.

Repaglinida [Inn-Spanish] Pharmacology

Repaglinide is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.

Repaglinida [Inn-Spanish] Absorption

Rapid (bioavailability is 56%)

Repaglinida [Inn-Spanish] side effects and Toxicity

LD50 >1 g/kg (rat) (W. Grell)

Repaglinida [Inn-Spanish] Patient Information


Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.

Repaglinida [Inn-Spanish] Organisms Affected

Humans and other mammals